These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17877883)
1. Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction. Kumar N; Pandey K; Das VN; Sinha PK; Topno RK; Verma N; Lal CS; Das P; Bhattacharya SK Ann Trop Med Parasitol; 2007 Oct; 101(7):649-51. PubMed ID: 17877883 [No Abstract] [Full Text] [Related]
2. Miltefosine for Indian visceral leishmaniasis. Agarwal PK N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12606744 [No Abstract] [Full Text] [Related]
3. Oral miltefosine for Indian visceral leishmaniasis. Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849 [TBL] [Abstract][Full Text] [Related]
4. Treatment of leishmaniasis with miltefosine: 2008 status. Berman JJ Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114 [TBL] [Abstract][Full Text] [Related]
5. Miltefosine for visceral leishmaniasis. Sherwood JA N Engl J Med; 2000 Mar; 342(12):895. PubMed ID: 10733377 [No Abstract] [Full Text] [Related]
6. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India. Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660 [No Abstract] [Full Text] [Related]
8. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277 [TBL] [Abstract][Full Text] [Related]
9. Miltefosine for Indian visceral leishmaniasis. Roca B N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397 [No Abstract] [Full Text] [Related]
10. An oral drug for leishmaniasis. Jacobs S N Engl J Med; 2002 Nov; 347(22):1737-8. PubMed ID: 12456848 [No Abstract] [Full Text] [Related]
11. New therapy for visceral leishmaniasis. Wkly Epidemiol Rec; 2002 Jun; 77(25):210-2. PubMed ID: 12132132 [No Abstract] [Full Text] [Related]
12. Oral miltefosine in the treatment of kala-azar. Mohan A; Seth S Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688 [No Abstract] [Full Text] [Related]
13. One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India. Burza S; Nabi E; Mahajan R; Mitra G; Lima MA Clin Infect Dis; 2013 Nov; 57(9):1363-4. PubMed ID: 23943824 [No Abstract] [Full Text] [Related]
14. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis? Sundar S; Singh A Expert Rev Anti Infect Ther; 2013 Feb; 11(2):117-9. PubMed ID: 23409817 [No Abstract] [Full Text] [Related]
15. Miltefosine for visceral leishmaniasis. Eibl H N Engl J Med; 2000 Mar; 342(12):894-5. PubMed ID: 10733376 [No Abstract] [Full Text] [Related]
16. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine]. Gangneux JP; Marty P Sante; 2001; 11(4):257-8. PubMed ID: 11861203 [No Abstract] [Full Text] [Related]
17. Visceral leishmaniasis simulating chronic liver disease: successful treatment with miltefosine. Avasthi R; Chaudhary SC; Khanna S Indian J Med Microbiol; 2009; 27(1):85-6. PubMed ID: 19172077 [No Abstract] [Full Text] [Related]
18. Availability of miltefosine for the treatment of kala-azar in India. Sundar S; Murray HW Bull World Health Organ; 2005 May; 83(5):394-5. PubMed ID: 15976883 [No Abstract] [Full Text] [Related]
19. Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases. Khandpur S; Chaturvedi P; Kumar U; Khaitan BK; Samantaray JC; Sharma VK Int J Dermatol; 2010 May; 49(5):565-9. PubMed ID: 20534094 [No Abstract] [Full Text] [Related]
20. Miltefosine presents new hope for leishmaniasis patients. Paterson R Lancet Infect Dis; 2002 Aug; 2(8):452. PubMed ID: 12150830 [No Abstract] [Full Text] [Related] [Next] [New Search]